Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase...
RNAi / ASO
Rona Therapeutics Initiates Phase II Study for RN0361 in Severe Hypertriglyceridemia
Shanghai-based Rona Therapeutics Inc. announced receiving approval from the US Food and Drug Administration (FDA)...
Visirna Therapeutics Announces Positive Phase III Results for Plozasiran in FCS Treatment
Shanghai-based Visirna Therapeutics announced positive topline results from the Phase III study of plozasiran in...
SynerK’s SNK-2726 Gets FDA Green Light for Phase I Hypertension Study
SynerK, an RNA-targeted therapy developer with operations in Boston, US, and Beijing and Suzhou, China,...
Suzhou Ribo Life Science’s RBD2080 siRNA Drug Receives Australian Clinical Trial Approval
China-based Suzhou Ribo Life Science Co., Ltd announced that its siRNA drug RBD2080 has received...
Suzhou Ribo and Boehringer Ingelheim Reach Pre-Clinical Milestone in NASH/MASH Partnership
China-based Suzhou Ribo Life Science Co., Ltd has announced the achievement of a first pre-clinical...
Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform
US-based Alloy Therapeutics Inc. has announced a target-specific collaboration and license agreement with Sanofi (NASDAQ:...
Huadong Medicine Partners with SynerK PharmaTech for Hypertension siRNA Drug Development
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a strategic partnership agreement with SynerK...
CSPC Pharmaceutical’s SYH2062 Receives NMPA Clearance for Hypertension Treatment
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...
Youjia Biomedical and Livzon Pharmaceutical Group Ink Licensing Deal for siRNA Drug
China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd. has signed a licensing agreement with compatriot firm...
Rona Therapeutics’ RN0191 Showcases Positive Phase I Results at AHA Scientific Sessions
Shanghai-based nucleic acid drug developer Rona Therapeutics has announced the presentation of positive Phase I...
Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments
China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered...
Mirxes Holding Company Updates IPO Prospectus with 2024 Financials
Mirxes Holding Company Ltd, a Singapore-based RNA technology company specializing in blood-based miRNA test kit...
Youcare Pharmaceutical Group Gets NMPA Approval for YKYY015 Phase I Study
China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received approval from the...
AstraZeneca’s Wainzua Earns CHMP Nod for hATTR-PN Treatment in the EU
UK pharmaceutical juggernaut AstraZeneca (AZ, NASDAQ: AZN) has announced that Wainzua (eplontersen), an RNA-targeted therapy...
Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments
Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked...
Novartis and Versant Ventures Launch Borealis Biosciences with a Focus on RNA Medicines for Kidney Diseases
Novartis (NYSE: NVS), a Swiss pharmaceutical heavyweight, has joined forces with the US venture capital...
Innovent Biologics and Sanegene Bio Commence Phase I Clinical Trial for Hypertension siRNA Drug
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, in collaboration with...
Rona Therapeutics Secures USD 35 Million in Series A+ Round to Advance Nucleic Acid Therapies
Rona Therapeutics, a Shanghai-based nucleic acid drug developer, has secured USD 35 million in a...
AusperBio Secures $37 Million in Series A Funding to Advance Hepatitis B Therapy AHB-137
AusperBio, a sino-American biotechnology company specializing in liver therapy development, has reportedly secured USD 37...